Have a feature idea you'd love to see implemented?
Let us know!
NVCR NovoCure Ltd
Price (delayed)
$14.72
Market cap
$1.59B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.57
Enterprise value
$2.1B
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating
Highlights
NVCR's EPS is up by 13% since the previous quarter and by 4.3% year-on-year
The net income has grown by 12% from the previous quarter and by 3.2% YoY
The company's quick ratio fell by 10% YoY but it rose by 3.8% QoQ
NovoCure's debt has increased by 15% YoY and by 13% from the previous quarter
The equity has declined by 13% year-on-year
Key stats
What are the main financial stats of NVCR
Market
Valuations
Earnings
Shares outstanding
108.22M
Market cap
$1.59B
Enterprise value
$2.1B
Price to book (P/B)
4.38
Price to sales (P/S)
2.88
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.82
Revenue
$549.96M
EBIT
-$185.06M
EBITDA
-$173.86M
Free cash flow
-$104.47M
Per share
Balance sheet
Liquidity
EPS
-$1.57
Free cash flow per share
-$0.97
Book value per share
$3.36
Revenue per share
$5.11
TBVPS
$11.26
Total assets
$1.21B
Total liabilities
$850.42M
Debt
$675.2M
Equity
$361.75M
Working capital
$923.66M
Debt to equity
1.87
Current ratio
6.46
Quick ratio
6.22
Net debt/EBITDA
-2.91
Margins
Efficiency
Dividend
EBITDA margin
-31.6%
Gross margin
75.8%
Net margin
-30.7%
Operating margin
-33.6%
Return on assets
-14.6%
Return on equity
-45.7%
Return on invested capital
-13.7%
Return on capital employed
-17.7%
Return on sales
-33.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NVCR stock price
How has the NovoCure stock price performed over time
Intraday
1.24%
1 week
-5.7%
1 month
-11.86%
1 year
-0.41%
YTD
-1.41%
QTD
-5.82%
Financial performance
How have NovoCure's revenue and profit performed over time
Revenue
$549.96M
Gross profit
$416.97M
Operating income
-$185.06M
Net income
-$168.7M
Gross margin
75.8%
Net margin
-30.7%
NovoCure's operating margin has increased by 17% QoQ and by 10% YoY
NovoCure's net margin has increased by 16% from the previous quarter and by 10% YoY
NovoCure's operating income has increased by 14% QoQ and by 2.9% YoY
The net income has grown by 12% from the previous quarter and by 3.2% YoY
Growth
What is NovoCure's growth rate over time
Valuation
What is NovoCure stock price valuation
P/E
N/A
P/B
4.38
P/S
2.88
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.82
NVCR's EPS is up by 13% since the previous quarter and by 4.3% year-on-year
The price to book (P/B) is 80% lower than the 5-year quarterly average of 22.1 and 4.8% lower than the last 4 quarters average of 4.6
The equity has declined by 13% year-on-year
NVCR's price to sales (P/S) is 83% lower than its 5-year quarterly average of 16.5 and 13% lower than its last 4 quarters average of 3.3
The company's revenue rose by 8% YoY and by 4.6% QoQ
Efficiency
How efficient is NovoCure business performance
NVCR's return on sales is up by 17% since the previous quarter and by 10% year-on-year
NovoCure's ROIC has increased by 15% from the previous quarter but it has decreased by 3% YoY
NovoCure's return on equity has decreased by 14% YoY but it has increased by 9% QoQ
The company's return on assets rose by 14% QoQ
Dividends
What is NVCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NVCR.
Financial health
How did NovoCure financials performed over time
NovoCure's total assets is 43% more than its total liabilities
NovoCure's total liabilities has increased by 14% YoY and by 12% QoQ
The company's quick ratio fell by 10% YoY but it rose by 3.8% QoQ
NovoCure's debt is 87% more than its equity
NVCR's debt to equity is up by 33% YoY and by 13% QoQ
NovoCure's debt has increased by 15% YoY and by 13% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.